MG
IMVT icon

Michael Gelband’s Immunovant IMVT Stock Holding History

Michael Gelband’s Portfolio IMVT Stock Details IMVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-21,941
Closed -$545K – 1802
2026
Q1 		$545K Sell
21,941
-104,680
-83% -$2.71M ﹤0.01% 1172
2025
Q4 		$3.22M Buy
+126,621
New +$2.82M 0.03% 615
2025
Q3 		– Sell
-241,694
Closed -$3.87M – 1762
2025
Q2 		$3.87M Buy
241,694
+79,574
+49% +$1.2M 0.03% 498
2025
Q1 		$2.77M Buy
162,120
+132,887
+455% +$2.78M 0.03% 586
2024
Q4 		$724K Buy
+29,233
New +$829K 0.01% 1043
2024
Q3 		– Sell
-126,660
Closed -$3.34M – 1824
2024
Q2 		$3.34M Buy
126,660
+57,506
+83% +$1.64M 0.02% 584
2024
Q1 		$2.23M Buy
69,154
+20,249
+41% +$739K 0.02% 655
2023
Q4 		$2.06M Buy
+48,905
New +$1.8M 0.01% 566
2023
Q3 		– Sell
-37,135
Closed -$704K – 1900
2023
Q2 		$704K Sell
37,135
-11,460
-24% -$214K 0.01% 1227
2023
Q1 		$754K Buy
+48,595
New +$843K 0.01% 1229
2022
Q4 		– Sell
-22,776
Closed -$127K – 1853
2022
Q3 		$127K Sell
22,776
-290,580
-93% -$1.42M ﹤0.01% 1715
2022
Q2 		$1.22M Buy
313,356
+15,286
+5% +$66K 0.02% 989
2022
Q1 		$1.64M Buy
298,070
+97,026
+48% +$604K 0.02% 881
2021
Q4 		$1.71M Buy
201,044
+67,844
+51% +$560K 0.02% 820
2021
Q3 		$1.16M Sell
133,200
-32,217
-19% -$291K 0.02% 960
2021
Q2 		$1.75M Buy
+165,417
New +$2.31M 0.02% 746
2020
Q1 		– Sell
-21,800
Closed -$346K – 1341
2019
Q4 		$346K Buy
+21,800
New +$244K 0.01% 1066

Other funds holding IMVT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Michael Gelband's IMVT Position: Q2 2026 in Review

Michael Gelband sold out of Immunovant (IMVT) in Q2 2026, closing a stake of 21,941 shares — an estimated $545K sold.

Michael Gelband first reported a position in IMVT in Q4 2019 and held it in 17 quarters. The position peaked at $3.87M in Q2 2025. 224 funds tracked by Wall St. Rank hold IMVT as of Q2 2026.

  • Michael Gelband reported no remaining Immunovant position as of Q2 2026 after selling out during the quarter.
  • Michael Gelband sold 21,941 Immunovant shares in Q2 2026, an estimated $545K.
  • Michael Gelband first reported a position in Immunovant in Q4 2019 and held it in 17 quarters.
  • Michael Gelband's Immunovant position peaked at $3.87M in Q2 2025.
  • 224 funds tracked by Wall St. Rank held Immunovant as of Q2 2026.

Based on ExodusPoint Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.